Ankylosing Spondylitis News and Research

RSS
Ankylosing Spondylitis (AS) is a painful and progressive form of spinal arthritis and symptoms of inflammatory back pain often first present in people before age 35. It typically begins in the late teens and early twenties and in severe cases may result in fusing spinal vertebrae and may cause structural damage to hips and other joints. Often misdiagnosed as "just back pain" or undifferentiated arthritis, AS is a systemic inflammatory disease that, in addition to its effect on the spine, can affect internal organs, peripheral joints and vision. The Arthritis Research Campaign, estimates that on the European continent, AS prevalence ranges from 0.2 to 1 percent of the entire population. The Spondylitis Association of America estimates that between 350,000 and one million people in the U.S. suffer from Ankylosing Spondylitis.
Research findings provide insight into mechanisms underlying differences in efficacy of anti-TNF drugs

Research findings provide insight into mechanisms underlying differences in efficacy of anti-TNF drugs

CreakyJoints publishes new guidelines for rheumatoid arthritis patients and caregivers

CreakyJoints publishes new guidelines for rheumatoid arthritis patients and caregivers

CreakyJoints announces first patient-friendly guidelines for rheumatoid arthritis

CreakyJoints announces first patient-friendly guidelines for rheumatoid arthritis

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

FDA approves new biosimilar for multiple inflammatory diseases

FDA approves new biosimilar for multiple inflammatory diseases

Swimming can be effective option for treating patients with fibromyalgia pain

Swimming can be effective option for treating patients with fibromyalgia pain

Facebook advertising could be more effective way of identifying IBP patients

Facebook advertising could be more effective way of identifying IBP patients

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

Inflectra (infliximab-dyyb) approved for multiple indications

Inflectra (infliximab-dyyb) approved for multiple indications

Global research links genes to five common, hard-to-treat inflammatory diseases

Global research links genes to five common, hard-to-treat inflammatory diseases

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients

Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients

CHMP recommends approval of Cosentyx in Europe to treat patients with AS and PsA, says Novartis

CHMP recommends approval of Cosentyx in Europe to treat patients with AS and PsA, says Novartis

Scientists calculate precise measurements of heritability in nine pediatric-onset autoimmune diseases

Scientists calculate precise measurements of heritability in nine pediatric-onset autoimmune diseases

ACR releases new recommendations for treatment of AS and non-radiographic axial SpA

ACR releases new recommendations for treatment of AS and non-radiographic axial SpA

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

Study shows that ankylosing spondylitis can be predicted by low birth weight

Study shows that ankylosing spondylitis can be predicted by low birth weight